Guidelines for Environmental Infection Control
Recommendations of CDC and the Healthcare Infection Control Pr

Prepared by
Lynne Sehulster, Ph.D. 1
Raymond Y.W. Chinn, M.D. 2
1Division of Healthcare Quality Promotion
National Center for Infectious Diseases
2HICPAC member
Sharp Memorial Hospital
San Diego, California
The material in this report originated in the National Center for Infectious Diseases, James M. Hughes, M.D., Director; and t Director.

Summary
The health-care facility environment is rarely implicated in disease transmission, except inadvertent exposures to environmental pathogens (e.g., Aspergillus spp. and Legion t tuberculosis and varicella-zoster virus) can result in adverse patient outcomes and cc infection-control strategies and engineering controls can effectively prevent these infectic pseudo-outbreaks can be minimized by 1) appropriate use of cleaners and disinfectants automated endoscope reprocessors or hydrotherapy equipment); 3) adherence to wat standards for specialized care environments (e.g., airborne infection isolation rooms, pr management of water intrusion into the facility. Routine environmental sampling is not hemodialysis settings and other situations where sampling is directed by epidemiologic , control decisions.

This report reviews previous guidelines and strategies for preventing environment-a recommendations. These include 1) evidence-based recommendations supported by studie Administration, U.S. Environmental Protection Agency, U.S. Department of Labor, O Department of Justice); 3) guidelines and standards from building and equipment profes Association for the Advancement of Medical Instrumentation, and American Society of I. recommendations derived from scientific theory or rationale; and 5) experienced opinio The report also suggests a series of performance measurements as a m Introduction
Parameters of the Report

This report, which contains the complete list of recommendations with pertinent refer

Control in Health-Care Facilities. The full four-part guidelines will be available on CI website. Relative to previous CDC guidelin

- revises multiple sections (e.g., cleaning and disinfection of environmental surfa
 regulated medical waste) from previous editions of CDC's Guideline for i
- incorporates discussions of air and water environmental concerns from CDC
  - consolidates relevant environmental infection-control meas
- includes two topics not addressed in previous CDC guidelines --- infection-contr

water quality in hemodialysis:

In the full guidelines, Part I, Background Information: Environmental Infection Con review of the relevant scientific literature. Attention is given to engineering and infe renovation, and repair of health-care facilities. Use of an infection-control risk assess other activities expected to generate dust or water aerosols. Also reviewed in Part catastrophic events (e.g., flooding, sewage spills, loss of electricity and ventilation, o environmental surfaces, laundry, plants, animals, medical wastes, cloth furnishings: facilities. Part III and Part IV of the full guidelines provide references (for the Part II (this report) contains recommendations for environmental infection control i preventing infections associated with air, water, or other elements of the environment divisions within CDC's National Center for Infectious Diseases and the Healthcare Inf a 12-member group that advises CDC on concerns related to the surveillance, preve primarily in U.S. health-care facilities. In 1999, HICPAC's infection-control focus wa health care is provided (e.g., outpatient surgical centers, urgent care centers, clinics, (n nursing facilities). The topics addressed in this report are applicable to the majority o intended for use primarily by infection-control practitioners, epidemiologists, emg managers, information systems professionals, administrators, environmental service pi
- infection-control impact of ventilation system and
- establishment of a multidisciplinary team to conduct ii
- use of dust-control procedures and barriers during construct
- environmental infection-control measures for special :
- use of airborne-particle sampling to monitor the effectiveness of
- procedures to prevent airborne contamination in operating rooms when ir
- guidance regarding appropriate indications for routine culturing of water as p
- guidance for recovering from water-system disruptions, water lk
- infection-control concepts for equipment using water from main lines (e.g., wat
- equipment, dental unit water lines, and automate
- environmental surface cleaning and disinfection strategies with re:
  - infection-control procedures for healt
  - use of animals in health care for activit
- managing the presence of service animals in
- infection-control strategies for when animals receive treatme
• a call to reinstate the practice of inactivating amplified cultures and stocks of microorganisms

Topics outside the scope of this report include 1) noninfectious adverse events (e.g., sick building syndrome), 2) environmental concerns in the home, 3) home health care, 4) terrorism, and 5) health-care--associated foodborne illness.

Wherever possible, the recommendations in this report are based on data from well-designed scientific studies. However, certain of these studies were conducted by using narrowly defined patient populations or specific health-care settings (e.g., hospitals versus long-term care facilities), making generalization of findings potentially problematic. Construction standards for residential home-care units. Similarly, infection-control measures indicated for immuno compromised patients are not necessary in those facilities where such patients are not present.

Other recommendations were derived from knowledge gained during infectious disease investigations in health-care facilities, where successful termination of the outbreak was often the result of multiple interventions, the majority of which cannot be independently and rigorously evaluated. This is especially true for construction situations involving air or water. Other recommendations were derived from empiric engineering concepts and may reflect industry standards rather than evidence-based conclusions.

Infections caused by the microorganisms described in this guideline are rare events, and the effect of these recommendations on infection rates in a facility may not be readily measurable. Therefore, the following steps to measure performance are suggested to evaluate these recommendations:

1. Document whether infection-control personnel are actively involved in all phases of a health-care facility's demolition, construction, and renovation. Activities should include performing a risk assessment of the necessary types of construction barriers, and daily monitoring and documenting of the presence of negative airflow within the construction zone or renovation area.

2. Monitor and document daily the negative airflow in AAI rooms and positive airflow in PPE rooms, especially when patients are in these rooms.

3. Perform assays at least once a month by using standard quantitative methods for heterotrophic and mesophilic bacteria in water used to prepare dialysate and for hemodialyzer reprocessing.

4. Evaluate possible environmental sources (e.g., water, laboratory solutions, or reagents) of specimen contamination when nontuberculous mycobacteria (NTM) of unlikely clinical importance are isolated from clinical cultures. If environmental contamination is found, eliminate the probable mechanism.

5. Document policies to identify and respond to water damage. Such policies should result in either repair and drying of wet structural or porous materials within 72 hours, or removal of the wet material if drying is unlikely within 72 hours.

Updates to Previous Recommendations

Contributors to this report reviewed primarily English-language manuscripts identified from reference searches using the National Library of Medicine's MEDLINE, bibliographies of published articles, and infection-control textbooks. All the recommendations may not reflect the opinions of all reviewers. This report updates the following published guidelines and recommendations:

CDC. Guideline for handwashing and hospital environmental control. MMWR 1998;37(No. 24).

Replaces sections on microbiologic sampling, laundry, infective waste, and housekeeping.

aspergillosis and Legionnaires disease; online version incorporates Appendices B, C, : Legionella spp.

CDC. Guidelines for preventing the transmission of mycobacterium tuberculosis in he:

CDC. Recommendations for preventing the spread of vancomycin resistance: recom

Advisory Committee (HICPAC). MMWR 1995;44(No. RR12). Supplements environ

Hospitals with Endemic VRE or Continued V

Garner JS, Hospital Infection Control Practices Advisory Committee. Guideline for

Epidemiol 1996;17:53--80. Supplements and updates topics in Part II --- Recommen

laundry, routine and terminal cleaning, airbo

Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR, Hospital Infection pre

vention of surgical site infection. Infect Control Hosp Epidemiol 1999;4:250--

cleaning/disinfection recommendations from the section, Intraoperat

U.S. Public Health Service, Infectious Diseases Society of America, Prevention of O

guidelines for the prevention of opportunistic infections in persons infected with hu

2002; 10:3--64. Supplements information regarding patient interact

CDC, Infectious Diseases Society of America, American Society of Blood and Marrow

infections among hematopoietic stem cell transplant recipients. Cytotherapy 2001;3

Infection Control.

Key Terms

Airborne infection isolation (AII) refers to the isolation of patients infected with o

diameter. This isolation area receives numerous air changes per hour (ACH) (>1 const

construction before 2001), and is under negative pressure, such that the direction of 
corridor) into the room. The air in an AII room is preferably exhausted to the outsid

filtered through a high-efficiency particulate air (HEPA) filter. The use of personal re

ese rooms when caring for TB or smallpox patients and for staff who lack immunity 
virus [VZV] infection).

Protective environment (PE) is a specialized patient-care area, usually in a hospita

from the room to the outside adjacent space). The combination of HEPA filtration, 

minimal leakage of air into the room creates an environment that can safely acc

hematopoietic stem cell transplant ( Immuc

Immunocompromised patients are those patients whose immune mechanisms are d

immunodeficiency virus [HIV] infection or congenital immune deficiency syndrome)
cardiac failure), or immunosuppressive therapy (e.g., radiation, cytotoxic chem

Immunocompromised patients who are identified as high-risk patients have the ge:

microorganisms. Patients in this subset include persons who are severely neutropenic 
count [ANC] of ≤500 cells/mL), allogeneic HSCT patients, and those who have receive 
myelogenous leukemia patient: 

Abbreviations

AAMI Association for the Advancement of Medi

ACH air changes per hour
As in previous CDC guidelines, each recommendation is categorized on the basis of existing scientific data, theoretic rationale, applicability, and possible economic effect. The recommendations are evidence-based wherever possible.
empiric infection-control or engineering principles, theoretic rationale, or from experience gained from events that cannot be readily studied (e.g., floods).

The HICPAC system for categorizing recommendations has been modified to include recommendations by state or federal regulations. Guidelines and standards published by the AIA, American Society of Heating, Refrigeration, and Air-Conditioning Engineers (ASHRAE), and the Association for the Advancement of Medical Instrumentation (AAMI) form the basis of certain recommendations. These standards reflect a consensus of expert opinions and extensive consultation with agencies of the U.S. Department of Health and Human Services. Compliance with these standards is usually voluntary. For example, the standards from AIA regarding construction and design of new or renovated health-care facilities have been adopted by reference by >40 states. Certain recommendations have two category ratings (e.g., Categories IA and IC), indicating the recommendation is evidence-based as well as a standard or regulation.

**Rating Categories**

Recommendations are rated according to the following categories:

- **Category IA.** Strongly recommended for implementation and strongly supported by well-designed experimental, clinical, or epidemiologic studies.
- **Category IB.** Strongly recommended for implementation and supported by certain experimental, clinical, or epidemiologic studies and a strong theoretic rationale.
- **Category IC.** Required by state or federal regulation, or representing an established association standard. (Note: Abbreviations for governing agencies and regulatory citations are listed where appropriate. Recommendations from regulations adopted at state levels are also noted. Recommendations from AIA guidelines cite the appropriate sections of the standards.)
- **Category II.** Suggested for implementation and supported by suggestive clinical or epidemiologic studies, or a theoretic rationale.
- **Unresolved issue.** No recommendation is offered. No consensus or insufficient evidence exists regarding efficacy.

**Recommendations --- Air**

I. **Air-Handling Systems in Health-Care Facilities**

A. Use AIA guidelines as minimum standards where state or local regulations are not in place for design and construction of ventilation systems in new or renovated health-care facilities. Ensure that existing structures continue to meet the specifications in effect at the time of construction (1). Category IC (AIA: 1.1.A, 5.4)


1. Ensure that heating, ventilation, air conditioning (HVAC) filters are properly installed and maintained to prevent air leakages and dust overloads (2,4,6,9). Category IB

2. Monitor areas with special ventilation requirements (e.g., AII or PE) for ACH, filtration, and pressure differentials (1,7,8,10--26). Category IB, IC (AIA: 7.2.C7, 7.2.D6)

   a. Develop and implement a maintenance schedule for ACH, pressure differentials, and filtration efficiencies by using facility-specific data as part of the multidisciplinary risk assessment. Take into account the age and reliability of the system.

   b. Document these parameters, especially the pressure differentials.

3. Engineer humidity controls into the HVAC system and monitor the control
a. Locate duct humidifiers upstream from the final filters.

b. Incorporate a water-removal mechanism into the system.

c. Locate all duct takeoffs sufficiently downstream from the humidifier so that moisture is completely absorbed.

4. Incorporate steam humidifiers, if possible, to reduce potential for microbial proliferation within the system, and avoid the use of cool-mist humidifiers. Category II


a. Locate exhaust outlets >25 ft from air-intake systems.

b. Locate outdoor air intakes >6 ft above ground or >3 ft above roof level.

c. Locate exhaust outlets from contaminated areas above roof level to minimize recirculation of exhausted air.

6. Maintain air intakes and inspect filters periodically to ensure proper operation (1,11--16, 27). Category IC

7. Bag dust-filled filters immediately upon removal to prevent dispersion of dust and fungal spores during transport within the facility (4,28). Category IB

a. Seal or close the bag containing the discarded filter.

b. Discard spent filters as regular solid waste, regardless of the area from which they were removed (28).

8. Remove bird roosts and nests near air intakes to prevent mites and fungal proliferation. Category IB

9. Prevent dust accumulation by cleaning air-duct grilles in accordance with facility-specific procedures and schedules and when rooms are not occupied by patients (1,10--16). Category IC, II (AIA: 7.31.D9, 9.31.D3, 10.31.D3, 11.31)

10. Periodically measure output to monitor system function; clean ventilation ducts as part of routine HVAC maintenance to ensure optimum performance (1,31,32). Category IC, II (AIA: 7.31.D10)

C. Use portable, industrial-grade HEPA filter units capable of filtration rates in the range of 300--800 ft$^3$/min to augment removal of respirable particles as needed (33).

1. Select portable HEPA filters that can recirculate all or nearly all of the room air. Category II

2. Portable HEPA filter units placed in construction zones can be used later in patient care areas, provided all internal and external surfaces are cleaned, and the filter or its performance is verified by appropriate particle testing. Category II

3. Situate portable HEPA units with the advice of facility engineers to ensure that all room air is filtered (34). Category II
4. Ensure that fresh-air requirements for the area

D. Follow appropriate procedures for use of areas with through-the-wall ventilation


1. Do not use such areas as PE rooms (I). Cat

2. Do not use a room with a through-the-wall ventilation unit as an AII room unless it can be demonstrated that all required AII engineering controls are met (I,34). Cat 7.2.C3)

E. Conduct an infection-control risk assessment (ICRA) and provide an adequate number of AII and PE rooms to meet the needs of the patient population (I,2,7,8,17,19,20,34). Cat 7.2.D3

F. When ultraviolet germicidal irradiation (UVGI) is used as a supplemental engineering control, it should be installed on the wall near the ceiling or suspended from the ceiling as an upper air unit; 2) in the air-return duct of an AII area; or 3) in designated enclosed areas or booths for sputum induction (34).

G. Seal windows in buildings with centralized HVAC systems, including PE areas (1).

H. Keep emergency doors and exits from PE rooms closed except during an emergency (I). Category II

I. Develop a contingency plan for backup capacity in the event of a general power failure (I,45). Category IC (AIA: 7.2.C, 7.2.D)

1. Emphasize restoration of appropriate air quality and ventilation conditions in AII rooms, PE rooms, operating rooms, emergency departments, and intensive care units (I,45). Cat 1.5.A1; JCAHO: EC 1.4

2. Deploy infection-control procedures to protect occupants until power and systems functions are restored (I,36,45). Cat 5.1, 5.2; JCAHO: EC 1.

J. Do not shut down HVAC systems in patient-care areas except for maintenance, repair, testing of emergency backup capacity, or new construction (I,46). Category IB, IC (AIA: 5.1, 5.2)

1. Coordinate HVAC system maintenance with infection-control staff and relocate immunocompromised patients if necessary (I,34). Cat 5.1, 5.2

2. Provide backup emergency power and air-handling and pressurization systems to maintain filtration, constant ACH, and pressure differentials in PE rooms, AII rooms, and other critical-care areas (I,37,47).

3. For areas not served by installed emergency ventilation and backup systems, patients in those areas (33). Cat 5.1, 5.2

4. Coordinate system startups with infection-control staff to protect patients (I,46). Cat 5.1, 5.2

5. Allow sufficient time for ACH to clean the air once the system is operational (Table 1) (I,33). Cat 5.1, 5.2
K. HVAC systems serving offices and administrative areas may be shut down for energy conservation purposes, but the shutdown must not alter or adversely affect pressure differentials maintained in laboratories or critical care areas with specific ventilation requirements (i.e., PE rooms, AII rooms, operating rooms).

L. Whenever possible, avoid inactivating or shutting down the entire HVAC system, especially in acute care facilities.

M. Whenever feasible, design and install fixed backup ventilation systems for new or renovated construction of PE rooms, AII rooms, operating rooms, and other critical-care areas identified by ICRA (1).

II. Construction, Renovation, Remediation, and Demolition

A. Establish a multidisciplinary team that includes infection-control staff to coordinate proactive preventive measures at the inception; produce and maintain summary statements of the team's activities (1,9,11,16,38,48--51). Category IB, IC (AIA: 5.1)

B. Educate both the construction team and health-care staff in immunocompromised patient care areas regarding the airborne infection risks associated with construction projects, dispersal of fungal spores during such activities, and methods to control the dissemination of fungal spores (11--16,27,50,52--56).

C. Incorporate mandatory adherence agreements for infection control into construction contracts, with penalties for noncompliance and mechanisms to ensure timely correction of problems (1,11,13--16,27,50).

D. Establish and maintain surveillance for airborne environmental disease (e.g., aspergillosis) as appropriate during construction, renovation, repair, and demolition activities to ensure the health and safety of immunocompromised patients (27,57--59).

1. Using active surveillance, monitor for airborne infections in immunocompromised patients (27,37,57,58).

2. Periodically review the facility's microbiologic, histopathologic, and postmortem data to identify additional cases (27,37,57,58).

3. If cases of aspergillosis or other health-care--associated airborne fungal infections occur, aggressively pursue the diagnosis with tissue biopsies and cultures as feasible (11,13--16,27,50,57--59).

E. Implement infection-control measures relevant to construction, renovation, maintenance, demolition, and repair (1,16,49,50,60).

1. Before the project gets under way, perform an ICRA to define the scope of activity and the need for barrier measures (1,11,13--16,48--51,60). Category IB, IC (AIA: 5.1, 5.2)

a. Determine if immunocompromised patients may be at risk for exposure to fungal spores from dust generated during the project (13--16,48,51).

b. Develop a contingency plan to prevent such exposures (13--16,48,51).

2. Implement infection-control measures for external demolition and construction activities (11,13--16,50,61,62).

a. Determine if the facility can operate temporarily on recirculated air; if feasible, seal off adjacent air intakes.

b. If this is not possible or practical, check the low-efficiency (roughing) filter banks frequently and replace as needed to avoid buildup of particulates.

c. Seal windows and reduce wherever possible other sources of outside air intrusion.
especially in PE areas.

3. Avoid damaging the underground water system (i.e., buried pipes) to prevent IB, IC (AIA: 5.1)

4. Implement infection-control measures for internal construction activities (IB, IC (AIA: 5.1, 5.2)

a. Construct barriers to prevent dust from construction areas from entering patient care areas; ensure that barriers are impermeable to fungal spores and in compliance with local codes (1,45,48,49,55,64)

b. Seal off and block return air vents if rigid barriers are used for containment (1,16,50)

c. Implement dust-control measures on surfaces and divert pedestrian traffic away from work zones (1,48,49,64)

d. Relocate patients whose rooms are adjacent to work zones, depending on the immune status, the scope of the project, the potential for generation of dust or water aerosols, and the methods used to control these aerosols (1,64,65)

5. Perform those engineering and work-site related infection-control measures as needed for internal construction, repairs, and renovations (IB, IC (AIA: 5.1, 5.2)

a. Ensure proper operation of the air-handling system in the affected area after erection of barriers and before the room or area is set to negative pressure (39,47,50,64)

b. Create and maintain negative air pressure in work zones adjacent to patient care areas and ensure that required engineering controls are maintained (1,48,49,51,64,66)

c. Monitor negative airflow inside rigid barriers (1,67)

d. Monitor barriers and ensure integrity of the construction barriers; repair gaps or breaks in barrier joints (1,65,66,68)

e. Seal windows in work zones if practical; use window chutes for disposal of large pieces of debris as needed, but ensure that the negative pressure differential for the area is maintained (1,13,48)

f. Direct pedestrian traffic from construction zones away from patient care areas to minimize dispersion of dust (1,13--16,44,48--51,64)

g. Provide construction crews with 1) designated entrances, corridors, and elevators wherever practical; 2) essential services (e.g., toilet facilities) and convenience services (e.g., vending machines); 3) protective clothing (e.g., coveralls, footgear, and headgear) for travel to patient care areas; and 4) a space or anteroom for changing clothing and equipment (1,11,13--16,44)

h. Clean work zones and their entrances daily by 1) wet-wiping tools and tool carts before their removal from the work zone; 2) placing mats with tacky surfaces inside the entrance; and 3) covering debris and securing this covering before removing debris from the work zone (1,11,13--16,44)

i. In patient-care areas, for major repairs that include removal of ceiling tile plastic sheets or prefabricated plastic sheets that contain dust; use a negative pressure system within this enclosure to remove dust before removing debris from the work zone (1,11,13--16,44)
portable HEPA filter capable of filtration rates of 300--800 ft³/min., or exhaust air directly to the outside (16,48--50).

j. Upon completion of the project, clean the work zone according to facility procedures and remove debris before removing rigid barriers (1,11,13--16,48--50).

k. Flush the water system to clear sediment from pipes to minimize waterborne microorganism proliferation (1,63).

l. Restore appropriate ACH, humidity, and pressure differential; clean or replace air filters; dispose of spent filters (3,4,28,47).

F. Use airborne-particle sampling as a tool to evaluate barrier integrity (3,70). Category II

G. Commission the HVAC system for newly constructed health-care facilities and renovated spaces before occupancy and use, with emphasis on ensuring proper ventilation for operating rooms, AII rooms, and PE areas (1,70--72). Category IC (AIA: 5.1; ASHRAE: 1--1996)

H. No recommendation is offered regarding routine microbiologic air sampling before, during, or after construction, or before or during occupancy of areas housing immunocompromised patients (9,48,49,51,64,73,74). Unresolved issue

I. If a case of health-care--acquired aspergillosis or other opportunistic environmental fungal disease occurs during or immediately after construction, implement appropriate follow-up measures (40,48,75--78). Category IB

1. Review pressure-differential monitoring documentation to verify that pressure differentials in the construction zone and in PE rooms are appropriate for their setting; Category IB, IC (AIA: 5.1)

2. Implement corrective engineering measures to restore proper pressure differentials as needed; Category IB, IC (AIA: 5.1)

3. Conduct a prospective search for additional cases and intensify retrospective epidemiologic review of the hospital's medical and laboratory records (27,48,76,79,80). Category IB

4. If no epidemiologic evidence of ongoing transmission exists, continue routine maintenance in the area to prevent health-care--acquired fungal disease (27,75). Category IB

J. If no epidemiologic evidence exists of ongoing transmission of fungal disease, conduct an environmental assessment to find and eliminate the source (11,13--16,27,44,49--51,60,81).

1. Collect environmental samples from potential sources of airborne fungal spores than settle plates (2,4,11,16,27,44,49,50,64,65,81--86). Category IB

2. If either an environmental source of airborne fungi or an engineering problem is identified, promptly perform corrective measures to route of entry (49,60).

3. Use an EPA-registered antifungal biocide (e.g., copper-8-quinolinolate) for decontamination; Category IB

4. If an environmental source of airborne fungi is not identified, review infection control measures to identify potential areas for correction (88,89). Category IB

5. If possible, perform molecular subtyping of Aspergillus spp. isolated from clinical samples to determine their identities (90--94). Category II
K. If air-supply systems to high-risk areas (e.g., PE rooms) are not optimal, use portable, industrial-grade HEPA filters on a temporary basis until rooms with optimal air-handling systems become available (1,13–16,27,50).

III. Infection Control and Ventilation Requirements

A. Minimize exposures of severely immunocompromised patients (e.g., solid-organ transplant patients or allogeneic neutropenic patients) to activities that might cause aerosolization of fungal spores (e.g., vacuuming or disruption of ceiling tiles) (37,48,51,73).

B. Minimize the length of time that immunocompromised patients in PE are outside their rooms for diagnostic procedures and other activities (37,62).

C. Provide respiratory protection for severely immunocompromised patients when activities; consult the most recent revision of CDC's Guideline for Prevention regarding the appropriate type of respiratory protection.

D. Incorporate ventilation engineering specifications and dust-controlling processes into the planning and construction of new PE units (Figure 1).

1. Install central or point-of-use HEPA filters for supply (incoming) air (1,2,27,47.2.D).

2. Ensure that rooms are well-sealed by 1) properly constructing windows, doors, and intake and exhaust ports; 2) maintaining ceilings that are smooth and free of fissures, open joints, and crevices; 3) sealing walls above and below the ceiling; and 4) monitoring (1,27,44,100,101). Category IB, IC.

3. Ventilate the room to maintain >12 ACH (1,27,37,100).

4. Locate air supply and exhaust grilles so that clean, filtered air enters from one side of the room, flows across the patient's bed, and exits from the opposite side of the room (1,27,100,101). Category IC.

5. Maintain positive room air pressure (>2.5 Pa [0.01-inch water gauge]) in relation to the corridor (Table 7.2).

6. Maintain airflow patterns and monitor these on a daily basis by using permanently installed visual means of detecting airflow in new or renovated construction, or by using other visual methods (e.g., flutter strips or smoke tubes) in existing PE units. Document.

7. Install self-closing devices on all room exit doors in PE rooms.

E. Do not use laminar air flow systems in newly constructed PE units (99,101).

F. Take measures to protect immunocompromised patients who would benefit from an airborne infectious disease (e.g., acute VZV infection or tuberculosis).

1. Ensure that the patient's room is designed to maintain positive pressure.

2. Use an anteroom to ensure appropriate air-balance relationships and provide a HEPA filter in the exhaust return air must be recirculated (1,100) (Figure 2). Category IC.

3. If an anteroom is not available, place the patient in AII and use portable, inducers to the room (33). Category IC.
G. Maintain backup ventilation equipment (e.g., portable units for fans or filters) in areas and take immediate steps to restore the fixed ventilation system.

IV. Infection-Control and Ventilation Requirements for AII Rooms

A. Incorporate certain specifications into the planning and construction or renovation of AII units.

1. Maintain continuous negative air pressure (2.5 Pa [0.01 inch water gauge]) in relation to the air pressure in the corridor; monitor air pressure periodically, preferably daily, with audible manometers or smoke tubes at the door (for existing AII rooms), or with permanently installed visual monitoring mechanisms. Document the results of monitoring.

2. Ensure that rooms are well-sealed by properly constructing windows, doors, and air-intake and exhaust ports; when monitoring indicates air leakage, locate the leakage and make necessary repairs.

3. Install self-closing devices on all AII room exit doors.

4. Provide ventilation to ensure >12 ACH for renovated rooms and new rooms, >6 ACH for existing AII rooms.

5. Direct exhaust air to the outside, away from air-intake and populated areas. If this is not practical, air from the room can be recirculated after passing through a HEPA filter.

B. Where supplemental engineering controls for air cleaning are indicated from a risk assessment of the AII area, install UVGI units in the exhaust air ducts of the HVAC system to supplement HEPA filtration or install UVGI fixtures on or near the ceiling.

C. Implement environmental infection-control measures for persons with diagnosed or suspected airborne infectious diseases.

1. Use AII rooms for patients with or suspected of having an airborne infection, enclosed booth that is engineered to provide:
   1. >12 ACH; 2) air supply and exhaust rate sufficient to maintain a 2.5 Pa (0.01 inch water gauge) negative pressure difference with respect to all surrounding spaces with a rate of >50 ft³/min; and 3) air exhausted directly outside away from air intake.
   
   2. Although airborne spread of viral hemorrhagic fever (VHF) has not been documented in a healthcare setting, prudence dictates placing a VHF patient in an AII room, preferably with an anteroom, to reduce the risk of occupational exposure to aerosolized infectious material in blood, vomitus, liquid stool, and respiratory secretions present in large amounts during the end stage of a patient's illness.

   a. If an anteroom is not available, use portable, industrial-grade HEPA filters in the patient's room to provide additional ACH.
equivalents for removing airborne particulates.

b. Ensure that health-care workers wear face shields or goggles with appropriate respirators when entering the rooms of VHF patients with prominent cough, vomiting, diarrhea, or hemorrhage (109).

3. Place smallpox patients in negative pressure rooms at the onset of their illness (36). Category II

D. No recommendation is offered regarding negative pressure or isolation for patients with Pneumocystis carinii pneumonia (111–113). Unresolved issue.

E. Maintain backup ventilation equipment (e.g., portable units for fans or filters) for operating rooms, and take immediate steps to restore the fixed ventilation system (1,34,47). Category IC (AIA: 7.2)

V. Infection-Control and Ventilation Requirements for Operating Rooms

A. Implement environmental infection-control and ventilation measures for operating rooms.

1. Maintain positive-pressure ventilation with respect to corridors and adjacent areas (1,114,115). Category IB, IC (AIA: Table 7.2)

2. Maintain >15 ACH, of which >3 ACH should be fresh air (1,116,117). Category IC (AIA: Table 7.2)

3. Filter all recirculated and fresh air through the appropriate filters, providing 90% efficiency (dust spot testing) at a minimum (1,118). Category IC (AIA: Table 7.3)

4. In rooms not engineered for horizontal laminar airflow, introduce air at the ceiling and exhaust air near the floor (1,115,119). Category IC (AIA: 7.31.D4)

5. Do not use ultraviolet (UV) lights to prevent surgical-site infections (115,120–126). Category IB

6. Keep operating room doors closed except for the passage of equipment, personnel, and patients, and limit entry to essential personnel (127,128). Category IB

B. Follow precautionary procedures for infectious TB patients who also require emergency surgery (34,129,130).


2. Intubate the patient in either the AII room or the operating room; if intubating in the operating room, do not allow the doors to open until 99% of the airborne contaminants are removed (Table 1) (34,117).

3. When anesthetizing a patient with confirmed or suspected TB, place a bacterial filter between the anesthesia circuit and patient’s airway to prevent contamination of anesthesia equipment or discharge of tubercle bacilli into the ambient air (130,132). Category IB

4. Extubate and allow the patient to recover in an AII room (34,117). Category IB

5. If the patient has to be extubated in the operating room, allow adequate time (Table 1), because extubation is a cough-producing procedure (34,117).
C. Use portable, industrial-grade HEPA filters temporarily for supplemental air cleaning during intubation and extubation for TB patients who require surgery (33,34,117). Category II

1. Position the units appropriately so that all room air passes through the filters; obtain engineering consultation to determine the appropriate placements (34). Category II

2. Switch the portable unit off during the surgical procedure. Category II

3. Provide fresh air as per ventilation standards for operating rooms; portable units do not meet the requirements for the number of fresh ACH (1,33,133). Category II

D. If possible, schedule TB patients as the last surgical cases of the day to maximize the time available for removal of airborne contamination. Category II

E. No recommendation is offered for performing orthopedic implant operations in rooms supplied with laminar airflow (118,120). Unresolved issue

F. Maintain backup ventilation equipment (e.g., portable units for fans or filters) for emergency ventilation of operating rooms, and take immediate steps to restore the fixed ventilation system (1,47). Category IB, IC (AIA: 5.1)

VI. Other Potential Infectious Aerosol Hazards in Health-Care Facilities

A. In settings where surgical lasers are used, wear appropriate personal protective equipment (PPE), including N95 or N100 respirators, to minimize exposure to laser plumes (129,135,136). Category IC (OSHA; 29 CFR 1910.134,139)

B. Use central wall suction units with in-line filters to evacuate minimal laser plumes (135--138). Category II

C. Use a mechanical smoke evacuation system with a high-efficiency filter to manage the generation of large amounts of laser plume, when ablating tissue infected with human papilloma virus (HPV) or performing procedures on a patient with extrapulmonary TB (34,136,137,139--141). Category II

Recommendations --- Water

I. Controlling the Spread of Waterborne Microorganisms

A. Practice hand hygiene to prevent the hand transfer of waterborne pathogens, an important source of infection (36,142--146). Category IA

B. Eliminate contaminated water or fluid environmental reservoirs (e.g., in equipment or solutions) wherever possible (142,147). Category IB

C. Clean and disinfect sinks and wash basins on a regular basis by using an EPA-registered product as set by facility policies. Category II

D. Evaluate for possible environmental sources (e.g., potable water) of specimen contamination when waterborne microorganisms (e.g., NTM) of unlikely clinical importance are isolated from clinical cultures (e.g., patient care); specimens are collected aseptically from sterile sites or, if postprocedural, colonization after use of tap water in patient care (148--151). Category IB

E. Avoid placing decorative fountains and fish tanks in patient-care areas; ensure disinfection and fountain maintenance if decorative fountains are used in public areas of the health-care facility (152). Category IB

II. Routine Prevention of Waterborne Microbial Contamination Within the Distribution System

A. Maintain hot water temperature at the return at the highest temperature allowable by state regulations or codes, preferably >124 ºF (>51 ºC), and maintain cold water temperature at <68 ºF (<20 ºC) (27). Category IC (States; ASHRAE: 12:2000)

B. If the hot water temperature can be maintained at >124 ºF (>51 ºC), explore engineering options (e.g., installing preset thermostatic valves in point-of-use fixtures) to help minimize the risk of scalding (153). Category II

C. When state regulations or codes do not allow hot water temperatures above the 110 ºF (35 ºC--43.3 ºC) for nursing care facilities or when buildings cannot be retrofitted for thermostatic mixing valves, follow either of these alternative preventive measures to minimize the growth of Legionella spp. in water systems (34,136,137,139--141). Category II
1. Periodically increase the hot water temperature to $\geq 150^\circ F$ ($\geq 66^\circ C$) at the point of use (153). Category II

2. Alternatively, chlorinate the water and then flush it through the system (153--155). Category II

D. Maintain constant recirculation in hot-water distribution systems serving Category II

III. Remediation Strategies for Distribution System

A. Whenever possible, disconnect the ice machine before planned water disruptions. Category II

B. Prepare a contingency plan to estimate water demands for the entire facility expected to result in extensive and heavy microbial or chemical contamination (45,156). Category IC (JCAHO)

C. When a significant water disruption or an emergency occurs, adhere to any advisory issued by the municipal water utility (157). Category IB, IC (Municipal order)

1. Alert patients, families, staff, and visitors not to consume water from drinking fountains, ice, or drinks made from municipal tap water, while the advisory is in effect, unless the water has been disinfected (e.g., by bringing to a rolling boil for $\geq 1$ minute (157)). Category IB, IC (Municipal order)

2. After the advisory is lifted, run faucets and drinking fountains at full flow for $\geq 5$ minutes, or use high-temperature water flushing or chlorination (153,157). Category IC, II (Municipal order; ASHRAE: 12:2000)

D. Maintain a high level of surveillance for waterborne disease among patients after a boil water advisory is lifted. Category II

E. Corrective decontamination of the hot water system might be necessary after a cross-connection with sewer lines has occurred. Category IC

1. Decontaminate the system when the fewest occupants are present in the building (e.g., nights or weekends) (27,153). Category IC

2. If using high-temperature decontamination, raise the hot-water temperature progressively flushing each outlet system for $\geq 5$ minutes (27,153). Category I

3. If using chlorination, add enough chlorine, preferably overnight, to achieve a free chlorine residual of $> 2$ mg/L ($> 2$ ppm) throughout the system (153). Category IC (ASHRAE: 12:2000)

   a. Flush each outlet until chlorine odor is detected.
   b. Maintain the elevated chlorine concentration in the system for $> 2$ (but $< 24$) hours.

4. Use a thorough flushing of the water system instead of chlorination if a highly chlorine-resistant microorganism (e.g., Cryptosporidium spp.) is suspected as the water contaminant. Category II

F. Flush and restart equipment and fixtures according to manufacturer's instructions. Category II
G. Change the pretreatment filter and disinfect the dialysis water system with an EPA-registered product to prevent colonization of the reverse osmosis membrane and downstream microbial contamination.

H. Run water softeners through a regeneration cycle to restore their capacity and function.

I. If the facility has a water-holding reservoir or water-storage tank, consult the facility engineer or local health department to determine whether this equipment needs to be drained, disinfected with an EPA-registered product, and refilled.

J. Implement facility procedures to manage a sewage system failure or flooding temporary transfer of patients or provision of services, and establish communication with the local health department to ensure that advisories are received in a timely manner.

K. Implement infection-control measures during sewage intrusion, flooding, and other water-related emergencies:
   1. Relocate patients and clean or sterilize supplies from affected areas.
   2. If hands are not visibly soiled or contaminated with proteinaceous material, include an alcohol-based hand rub in the hand hygiene process:
      1) before performing invasive procedures;
      2) before and after each patient contact; and
      3) whenever hand hygiene is indicated.
   3. If hands are visibly soiled or contaminated with proteinaceous material, use soap and bottled water for handwashing.
   4. If the potable water system is not affected by flooding or sewage contamination, process surgical instruments for sterilization according to standard procedures.
   5. Contact the manufacturer of the automated endoscope reprocessor (AER) for specific instructions on the use of this equipment during a water advisory.

L. Remediate the facility after sewage intrusion, flooding, or other water-related emergencies:
   1. Close off affected areas during cleanup procedures.
   2. Ensure that the sewage system is fully functional before beginning remediation.
   3. If hard-surfaced equipment, floors, and walls remain in good repair, ensure according to standard cleaning procedures.
   4. Clean wood furniture and materials (if still in good repair); allow them to dry thoroughly before restoring varnish or other surface coatings.
   5. Contain dust and debris during remediation and repair as outlined in air recommendations.

M. Regardless of the original source of water damage (e.g., flooding versus water leaks from point-of-use fixtures or roofs), remove wet, absorbent structural items (e.g., carpeting, wallboard, and wallpaper) and cloth furnishings if they cannot be easily and thoroughly cleaned and dried within 72 hours (e.g., moisture content <20% as determined by moisture meter readings); replace with new materials as soon as the underlying structure is declared by the facility engineer to be thoroughly dry.

IV. Additional Engineering Measures as Indicated by Epidemiologic Investigation for Controlling Waterborne, Healthcare-Associated Legionnaires Disease

A. When using a pulse or one-time decontamination method, superheat the water before draining if the water temperature is ≥170°F (71°C) or hyperchlorinate the system by flushing all outlets for ≥5 minutes with water containing >2 mg/L (2 ppm) free chlorine.
residual chlorine using a chlorine-based product registered by the EPA for water treatment \( (153, 155, 161-164) \). Category IC

B. After a pulse treatment, maintain both the heated water temperature at recommendation (Water: II A) wherever practical and permitted by state codes ppm) free residual chlorine at the tap by using a chlorine-based product registered by the EPA for water treatment \( (153, 165-169) \). Category IC

C. Explore engineering or educational options (e.g., install preset thermostatic mix each outlet) to minimize the risk of scalding for patient

D. No recommendation is offered for treating water in the facility's distribution system with chlorine dioxide, heavy metal ions (e.g., copper or silver), monochloramines, ozone, or UV light \( (170-188) \). Unresolved issue

V. General Infection-Control Strategies for Preventing Legionnaires Disease

A. Conduct an infection-control risk assessment of the facility to determine if patients present \( (27, 189, 190) \). Category IB

B. Implement general strategies for detecting and preventing Legionnaires disease in facilities that do not provide care for severely immunocompromised patients (i.e., facilities that do not have HSCT or solid-organ transplant programs) (see Appendix) \( (27, 189, 190) \). Category IB

1. Establish a surveillance process to detect health-care-associated Legionnaires disease \( (27, 189, 190) \). Category IB

2. Inform health-care personnel (e.g., infection control, physicians, patient-care staff) regarding the potential for Legionnaires disease to occur and measures to control health-care-associated legionellosis

3. Establish mechanisms to provide clinicians with laboratory tests (e.g., culture, urine antigen, direct fluorescence assay [DFA], and serology) for the diagnosis of Legionnaires disease \( (27, 189) \). Category IB

C. Maintain a high index of suspicion for health-care-associated Legionnaires disease on suspected cases, especially in patients at risk who do not require patients aged \( \geq 65 \) years; or patients with chronic underlying disease (e.g., diabetes, chronic obstructive lung disease) \( (27, 166, 190, 192-198) \).

D. Periodically review the availability and clinicians' use of laboratory diagnostic use of the tests on patients with diagnosed or suspected pneumonia is limited, enhance clinicians' use of the test(s) \( (193) \).

E. If one case of laboratory-confirmed, health-care-associated Legionnaires disease is suspected, health-care-associated Legionnaires disease occur during a 6-month period \( (181, 189, 191, 193, 199, 200) \). Category IB

1. Report the cases to state and local health departments \( (193, 199, 200) \). Category IC (States)

2. If the facility does not treat severely immunocompromised patients, conduct review of microbiologic, serologic, or culture data to look for previously unidentified cases of health-care-associated Legionnaires disease and surveillance for additional
3. If no evidence of continued health-care--associated transmission exists, continue intensive prospective surveillance for >2 months after the initiation of surveillance (27,181,189,191,193,199,200). Category IB

F. If there is evidence of continued health-care--associated transmission (i.e., a outbreak), conduct an environmental assessment to determine the source of Legionella spp. (199--207). Category IB

1. Collect water samples from potential aerosolized water sources (Box 1 and Box 2) (208). Category IB
2. Save and subtype isolates of Legionella spp. obtained from patients and the environment (163,199--207,209). Category IB
3. If a source is identified, promptly institute water system decontamination measures per recommendations (see Water IV) (164,210). Category IB
4. If Legionella spp. are detected in >1 culture (e.g., conducted at 2-week intervals during 3 months), reassess the control measures, modify them accordingly, and repeat the decontamination procedures; consider intensive use of techniques used in the and hyperchlorination (27,210,211). Category IB

G. If an environmental source is not identified during a Legionnaires disease outbreak, either defer decontamination pending identification of the source of Legionella spp. or proceed with decontamination of the hospital's water distribution system, with special attention to areas involved in the outbreak. Category II

H. No recommendation is offered regarding routine culturing of water systems in health-care facilities that do not have patient-care areas (i.e., PE or transplant units) for persons at high risk for Legionella spp. infection (see Appendix) (161,165,167,198,212--214). Unresolved issue

I. No recommendation is offered regarding the removal of faucet aerators in a

J. Keep adequate records of all infection-control measures and environmental test results for potable water systems. Category II

VI. Preventing Legionnaires Disease in Protective Environments and Transplant Units

A. When implementing strategies for preventing Legionnaires disease among severely immunocompromised patients housed in facilities with HSCT or solid-organ transplant programs, incorporate these specific surveillance and epidemiologic measures in addition to the steps outlined previously (see Appendix).

1. Maintain a high index of suspicion for legionellosis in transplant patients even when environmental surveillance cultures do not yield legionellae (189,215). Category IB
2. If a case occurs in a severely immunocompromised patient, or if severely immunocompromised patients are identified elsewhere in the hospital (e.g., PE or transplant units) and cases are identified elsewhere in the facility, conduct a combined epidemiologic investigation of Legionella spp. (189,210). Category IB

B. Implement culture strategies and potable water and fixture treatment measures. Category II
1. Depending on state regulations on potable water temperature in public buildings, hospitals housing patients at high risk for health-care-associated legionellosis should either maintain heated water with a minimum return temperature of $\geq 124^\circ F (\geq 51^\circ C)$ and cold water at $<68^\circ F (<20^\circ C)$, or chlorinate heated water to achieve 1--2 mg/L (1--2 ppm) of free residual chlorine at the tap (153--155,165,167--169,217).

2. Periodic culturing for legionellae in potable water samples from HSCT or solid-organ transplant units can be performed as part of a comprehensive strategy to prevent Legionnaires disease in these units (37,154,189,218).

3. No recommendation is offered regarding the optimal methodology (i.e., frequency or number of sites) for environmental surveillance cultures in HSCT or solid-organ transplant units. Unresolved issue

4. In areas with patients at risk, when *Legionella* spp. are not detectable in unit aerators monthly by using a chlorine EPA-registered product. If an EPA-registered chlorine disinfectant is not available, use a chlorine bleach solution (500--615 ppm [1:100 v/v dilution]) (153,187). Category II

C. If *Legionella* spp. are determined to be present in the water of a transplant unit longer detected by cultur:

1. Decontaminate the water supply as outlined previously (Water: IV) (27,37,153,164,210). Category IB

2. Do not use water from the faucets in patient-care rooms to avoid creating infectious aerosols (37,219). Category IB

3. Restrict severely immunocompromised patients from taking showers (37,219). Category IB

4. Use water that is not contaminated with *Legionella* spp. for HSCT patients' sponge baths (37,219). Category IB

5. Provide patients with sterile water for tooth brushing, drinking, and for flushing nasogastric tubing during legionellosis outbreaks (37,219). Category IB

D. Do not use large-volume room air humidifiers that create aerosols (e.g., by Venturi principle, ultrasound, or spinning disk) unless they are subjected to high-level disinfection and filled only with sterile water (27,37,201,220).

VII. Cooling Towers and Evaporative Condensers

A. When planning construction of new health-care facilities, locate cooling towers so that the drift is directed away from the air-intake system, and design the towers to minimize the volume of aerosol drift system, and design the towers to minimize the volume of aerosol drift

B. Implement infection-control procedures for operational cooling towers

1. Install drift eliminators (153,203,222). Category IC

2. Use an effective EPA-registered biocide on a regular basis

3. Maintain towers according to manufacturers' recommendations, and keep detailed maintenance and infection-control records, including environmental test results from legionellosis outbreak investigations (153). Category IC

C. If cooling towers or evaporative condensers are implicated in health-care--associated legionellosis outbreaks (199,203,221,223). Category IC
VIII. Dialysis Water Quality and Dialysate

A. Adhere to current AAMI standards for quality-assurance performance of devices and equipment used to treat, store, and distribute water in hemodialysis centers (both acute and maintenance [chronic] settings) and for hemodiafiltration. Unresolved

B. No recommendation is offered regarding whether more stringent requirements should be imposed in hemofiltration and hemodiafiltration. Unresolved


   a. Assay for heterotrophic, mesophilic bacteria (e.g., *Pseudomonas*).
   b. Do not use nutrient-rich media (e.g., blood)


E. Wherever practical, design and engineer water systems in dialysis settings to avoid incorporating joints, dead-end pipes, and unused branches and taps that can harbor bacteria (226--228,231,236). Category IA, IC (AAMI: ANSI/AAMI RD62:2001)

IX. Ice Machines and Ice

A. Do not handle ice directly by hand, and wash hands before obtaining ice. Category II

B. Use a smooth-surface ice scoop to dispense ice (243,244). Category II

1. Keep the ice scoop on a chain short enough that the scoop cannot touch the floor when not in use (243,244). Category II

2. Do not store the ice scoop in the ice container.

C. Do not store pharmaceuticals or medical solutions on ice intended for consumption. Category II

D. Machines that dispense ice are preferred to those that require ice to be removed manually.
E. Limit access to ice-storage chests, and keep container doors closed

F. Clean, disinfect, and maintain ice-storage chests on a regular basis. Category II

1. Follow the manufacturer's instructions for cleaning.
2. Use an EPA-registered disinfectant suitable for use on ice machines, dispensers, and storage chests. Category II
3. If instructions and EPA-registered disinfectants suitable for use on ice machines are not available, use a general cleaning/disinfecting regimen (Box 3) (244). Category II
4. Flush and clean ice machines and dispensers if they have not been disconnected before anticipated lengthy water disruptions. Category II

G. Install proper air gaps where the condensate lines meet the waste lines. Category II

H. Conduct microbiologic sampling of ice, ice chests, and ice-making machines a regular basis (244,248,249). Category II

X. Hydrotherapy Tanks and Pools

A. Drain and clean hydrotherapy equipment (e.g., Hubbard tanks, tubs, whirlpools, whirlpool spas, or birthing tanks) after each patient's use, and disinfect equipment surfaces and components by using an EPA-registered product in accordance with the manufacturer's instructions. Category II

B. In the absence of an EPA-registered product for water treatment, add sodium hypochlorite to the water:
   1. Maintain a 15-ppm chlorine residual in the water of small hydrotherapy tanks, Hubbard tanks, and tubs (250). Category II
   2. Maintain a 2-5 ppm chlorine residual in the water of whirlpools and whirlpool spas (251). Category II
   3. If the pH of the municipal water is in the basic range (e.g., when chloramine is used as the primary drinking water disinfectant in the community), consult the facility engineer regarding the possible need to adjust the pH of the water to a more acidic level before disinfection (252). Category II

C. Clean and disinfect hydrotherapy equipment after each use. Category II

D. Clean and disinfect inflatable tubs unless they are single-use equipment. Category II

E. No recommendation is offered regarding the use of antiseptic chemicals (e.g., chloramine-T) in the water during hydrotherapy sessions. Unresolved issue

F. Conduct a risk assessment of patients before their use of large hydrotherapy pools, deferring patients with draining wounds or fecal incontinence from pool use until their condition resolves. Category II

G. For large hydrotherapy pools, use pH and chlorine residual levels appropriate for an indoor pool as provided by local and state health agencies. Category IC (States)

H. No recommendation is offered regarding the use in health-care settings of whirlpool or spa equipment manufactured for home or recreational use. Unresolved issue

XI. Miscellaneous Medical Equipment Connected to Water Systems

A. Clean, disinfect, and maintain AER equipment according to the manufacturer's instructions to prevent inadvertent contamination of endoscopes and bronchoscopes with water.
1. To rinse disinfected endoscopes and bronchoscopes, use water of the highest quality practical for the system's engineering and design (e.g., sterile water or bacteriologically filtered water [water filtered through 0.1-0.2-µm filters]) (254-258). Category IB

2. Dry the internal channels of the reprocessed endoscope or bronchoscope by using a proven method (e.g., 70% alcohol followed by forced-air treatment) to lessen the proliferation of waterborne microorganisms and to help prevent biofilm formation (259-263). Category IB

B. Use water that meets nationally recognized standards set by the EPA for drinking water (<500 CFU/mL for heterotrophic plate count) for routine dental treatment output water (264-267). Category IC

C. Take precautions to prevent waterborne contamination of dental unit water lines and instruments.

1. After each patient, discharge water and air for a minimum of 20-30 seconds from any dental device connected to the dental water system that enters a patient's mouth (e.g., handpieces, ultrasonic scalers, or air/water syringes) (265,268). Category II

2. Consult with dental water-line manufacturers to 1) determine suitable methods and equipment to obtain the recommended water quality; and 2) determine appropriate methods for monitoring the water to ensure quality is maintained (265,269). Category II

3. Consult with the dental unit manufacturer regarding the need for periodic maintenance of antiretraction mechanisms (268,269). Category IB

Recommendations --- Environmental Services

I. Cleaning and Disinfecting Strategies for Environmental Surfaces in Patient Care Areas

A. Select EPA-registered disinfectants, if available, and use them in accordance with the manufacturer's instructions (EPA: 7 United States Code [USC] § 136 et seq.). Category IC

B. Do not use high-level disinfectants/liquid chemical sterilants for disinfection of either noncritical instruments and devices or any environmental surfaces; such use is counter to label instructions for these toxic chemicals (273-278). Category IC (Food and Drug Administration [FDA]: 21 CFR 801.5, 807.87.e)

C. Follow manufacturers' instructions for cleaning and maintaining noncritical medical equipment. Category II

D. In the absence of a manufacturer's cleaning instructions, follow certain procedures.

1. Clean noncritical medical equipment surfaces with a detergent/disinfectant registered hospital disinfectant with tuberculocidal claim (depending on the nature of the surface and the degree of contamination) in accordance with germicide label instructions (274). Category II

2. Do not use alcohol to disinfect large environmental surfaces (273). Category II

3. Use barrier protective coverings as appropriate for noncritical surfaces that 1) are touched frequently with gloved hands during the delivery of patient care; 2) are likely to become contaminated with blood or body substances; or 3) are difficult to clean (265). Category II

E. Keep housekeeping surfaces (e.g., floors, walls, tabletops) visibly clean on a regular basis and clean up spills promptly (279). Category II

1. Use a one-step process and an EPA-registered hospital detergent/disinfectant...
care areas where 1) uncertainty exists as to the nature of the soil on the surfaces (e.g., blood or body fluid contamination versus the presence of multidrug resistant organisms (272,274,280,281). Category II

2. Detergent and water are adequate for cleaning surfaces in nonpatient-care areas (e.g., administrative offices). Category II

3. Clean and disinfect high-touch surfaces (e.g., doorknobs, bed rails, light switches, and surfaces in and around toilets in patients' rooms) on a more frequent schedule than minimal-touch housekeeping surfaces. (Category II

4. Clean walls, blinds, and window curtains in patient-care areas when they

F. Do not perform disinfectant fogging in patient-care areas (270,285). Category IB

G. Avoid large-surface cleaning methods that produce mists or aerosols, or disperse dust in patient-care areas (37,48,51,73). Category IB

H. Follow proper procedures for effective uses of mops, cloths, and solutions. Category II

1. Prepare cleaning solutions daily or as needed, and replace with fresh solution (280,281). Category II

2. Change the mop head at the beginning of each day and also as required by facility policy, or after cleaning up large spills of blood or other body substances. Category II

3. Clean mops and cloths after use and allow to dry before reuse; or use single-use, disposable mop heads and cloths (282,286). Category II

I. After the last surgical procedure of the day or night, wet vacuum or mop operating room floors with a single-use mop and an EPA-registered hospital disinfectant (114). Category IB

J. Do not use mats with tacky surfaces at the entrances to operating rooms. Category IB

K. Use appropriate dusting methods for patient-care areas designated for immunocompromised patients (e.g., HSCT patients) (37,40,280). Category IB

1. Wet-dust horizontal surfaces daily by moistening a cloth with a small amount of an EPA-registered hospital detergent/disinfectant (37,40,280). Category IB

2. Avoid dusting methods that disperse dust (e.g., feather dusting) (40). Category IB

L. Keep vacuums in good repair and equip vacuums with HEPA filters for use in areas with patients at risk (37,40,289). Category IB

M. Close the doors of immunocompromised patients' rooms when vacuuming, waiving airborne dust (37,40,289). Category IB

N. When performing low- or intermediate-level disinfection of environmental surfaces, avoid unnecessary exposure of neonates to disinfectant residues on these surfaces by using EPA-registered germicides in accordance with manufacturers' instructions and safety advisories (271,290--292). Category IB

1. Do not use phenolics or any other chemical germicide to disinfect bassinets or incubators during an infant's stay (271,290--292). Category IB

2. Rinse disinfectant-treated surfaces, especially those treated with phenolics (290--292). Category IB
O. When using phenolic disinfectants in neonatal units, prepare solutions to correct concentrations in accordance with manufacturers' instructions, or use premixed formulations (271,290--292). Category IB, IC (EPA: 7 USC § 136 et seq.)

II. Cleaning Spills of Blood and Body Substances

A. Promptly clean and decontaminate spills of blood or other potentially infectious materials (293--300). Category IB, IC (OSHA: 29 CFR 1910.1030 § d.4.ii.A)

B. Follow proper procedures for site decontamination of spills of blood or blood-containing body fluids (293--300). Category IC (OSHA: 29 CFR 1910.1030 § d.4.ii.A)

1. Use protective gloves and other PPE appropriate for this task (293). Category IC (OSHA: 29 CFR 1910.1030 § d.3.i, ii)

2. If the spill contains large amounts of blood or body fluids, clean the visible matter with disposable absorbent material, and discard the used cleaning materials in appropriate, labeled containers (293,298,299,301,302). Category IC (OSHA: 29 CFR 1910.1030 § d.4.iii.B)

3. Swab the area with a cloth or paper towels moderately wetted with disinfectant, and allow the surface to dry (293,301). Category IC (OSHA: 29 CFR 1910.1030 § d.4.ii.A)

C. Use germicides registered by the EPA for use as hospital disinfectants and labeled tuberculocidal or registered germicides on the EPA Lists D and E (i.e., products with specific label claims for HIV or hepatitis B) to decontaminate spills of blood and other body fluids (293,301,303). Category IB (2/28/97; compliance document [CPL] 2.44D [11/99])

D. An EPA-registered sodium hypochlorite product is preferred, but if such products are not available, generic sodium hypochlorite solutions (e.g., household chlorine bleach) may be used. (293,301,304,307)

   1. Use a 1:100 dilution (500--615 ppm available chlorine) to decontaminate nonporous surfaces after cleaning a spill of either blood or body fluids in patient-care settings (293,301,304). Category IB

   2. If a spill involves large amounts of blood or body fluids, or if a blood or culture spill occurs in the laboratory, use a 1:10 dilution (5,000--6,150 ppm available chlorine) for the first application of germicide before cleaning (301).

III. Carpeting and Cloth Furnishings

A. Vacuum carpeting in public areas of health-care facilities and in general patient-care areas regularly with well-maintained equipment designed to minimize dust dispersion (44,305,306). Category IB

B. Periodically perform a thorough, deep cleaning of carpeting as determined by facility policy by using a method that minimizes the production of aerosols and leaves little or no residue (44,305,306). Category IB

C. Avoid use of carpeting in high-traffic zones in patient-care areas or where spills are likely (e.g., burn therapy units, operating rooms, laboratories, or intensive care units) (44,305,306,307). Category IB

D. Follow appropriate procedures for managing spills on carpeting.


E. Thoroughly dry wet carpeting to prevent the growth of fungi; replace carpeting that remains wet after 72 hours (37,160).

F. No recommendation is offered regarding the routine use of fungicidal or bactericidal treatments for carpeting in public areas of a healthcare facility or in general patient-care areas. Unresolved issue

G. Do not use carpeting in hallways and patient rooms in areas housing immunosuppressed patients (e.g., PE areas) (37,44). Category IB

H. Avoid using upholstered furniture and furnishings in high-risk patient-care area contamination (e.g., pediatrics units) (37).

I. No recommendation is offered regarding whether upholstered furniture and furnishings should be avoided in general patient-care areas. Unresolved issue

1. Maintain upholstered furniture in good repair. Category II

2. Maintain the surface integrity of the upholstery by repairs and replacements as needed for obvious tears, holes, contamination, or discoloration. Category II

3. If upholstered furniture in a patient's room requires cleaning to remove visible soil or body substance contamination, move that item to a maintenance area where it can be cleaned with a process appropriate for the type of upholstery material.

IV. Flowers and Plants in Patient-Care Areas

A. Flowers and potted plants need not be restricted from areas for immunocompetent patients (308--311). Category II

B. Designate care and maintenance of flowers and potted plants to staff not directly involved with patient care (309). Category II

C. If plant or flower care by patient-care staff is unavoidable, instruct the staff to wash hands with soap and water for at least 15 seconds or use an alcohol-based hand rub (309). Category II

D. Do not allow fresh or dried flowers, or potted plants, in patient-care areas for immunocompromised patients (37,51,308,312). Category II

V. Pest Control

A. Develop pest-control strategies, with emphasis on kitchens, cafeterias, laundries, central sterile supply areas, operating rooms, loading docks, construction activities, and other areas prone to insect infestations (313--315). Category II

B. Install screens on all windows that open to the outside; keep screens in good repair (314). Category IB

C. Contract for routine pest control service by a credentialed pest-control specialist who will tailor the application to the needs of a healthcare facility (315). Category II

D. Place laboratory specimens (e.g., fixed sputum smears) in covered containers for overnight storage (316,317). Category II

VI. Special Pathogens

A. Use appropriate hand hygiene, PPE (e.g., gloves), and isolation precautions during cleaning and disinfecting procedures (146,274,318,319). Category IB

B. Use standard cleaning and disinfection protocols to control environmental contamination with antibiotic-resistant, gram-positive cocci (e.g., methicillin-resistant Staphylococcus aureus, vancomycin intermediate sensitive Staphylococcus aureus, or vancomycin-resistant Enterococcus [VRE]) (318,320--322).

1. Pay close attention to cleaning and disinfection of high-touch surfaces in patient rooms, bed rails, doorknobs, or faucets (318,320--322). Category IB

2. Ensure compliance by housekeeping staff with cleaning and disinfection practices (318,320--322). Category IB

3. Use EPA-registered chemical germicides appropriate for the surface to be disinfected as specified by the manufacturer (318,320--322). Category IB
4. When contact precautions are indicated for patient care, use disposable patient-care items (e.g., blood pressure cuffs) wherever possible to minimize cross-contamination with multiple-resistant microorganisms.

5. Follow these same surface-cleaning and disinfecting measures for managing the environment of VRSA patients.

C. Environmental-surface culturing can be used to verify the efficacy of hospital policies and procedures before and after cleaning and disinfecting rooms that house patients with VRE.

1. Obtain prior approval from infection-control staff and the clinical laboratory before performing environmental-surface culturing.

2. Infection-control staff, with clinical laboratory staff consultation, must supervise all environmental culturing.

D. Thoroughly clean and disinfect environmental and medical equipment surfaces in accordance with manufacturers' instructions (271, 274, 319, 334).

E. Advise families, visitors, and patients regarding the importance of hand hygiene (e.g., respiratory secretions or fecal matter) to surfaces.

F. Do not use high-level disinfectants (i.e., liquid chemical sterilants) on environmental surfaces; such use is inconsistent with label instructions because of the toxicity of the chemicals (270, 273, 274, 278).

G. Because no EPA-registered products are specific for inactivating *Clostridium difficile* disinfection of environmental surfaces in accordance with guidance from the surveillance and epidemiology indicate ongoing transmission.

H. No recommendation is offered regarding the use of specific EPA-registered hospital disinfectants with respect to environmental control of *C. difficile*. Unresolved issue.

I. Apply standard cleaning and disinfection procedures to control environmental contamination with respiratory and enteric viruses in pediatric-care units and care areas for immunocompromised patients.

J. Clean surfaces that have been contaminated with body substances; perform low-to intermediate-level disinfection on cleaned surfaces with an EPA-registered disinfectant in accordance with the manufacturer's instructions (271, 293, 335).

K. Use disposable barrier coverings as appropriate to minimize surface contamination.

L. Develop and maintain cleaning and disinfection procedures in patient-care areas for Creutzfeldt-Jakob disease (CJD), for which no EPA-registered product exists.

1. In the absence of contamination with central nervous system tissue, extraordinary measures (e.g., use of 2N sodium hydroxide [NaOH] or applying full-strength sodium hypochlorite) are not needed for routine cleaning or terminal disinfection of a room housing a confirmed or suspected CJD patient.

2. After removing gross tissue from the surface, use either 1N NaOH or a sodium hypochlorite solution containing approximately 10,000--20,000 ppm available chlorine (dilutions of 1:5 to 1:3 v/v, respectively, of U.S. household chlorine bleach; contact the manufacturer's instructions (271, 322--327). Category II, IC.
products for advice) to decontaminate operating room or autopsy surfaces with central nervous system or cerebral CJD patient (273,337--342). Ca

a. The contact time for the chemical used during this process
b. Blot up the chemical with absorbent material and rinse through
c. Discard the used, absorbent material into appropriate waste containers.

3. Use disposable, impervious covers to minimize body substance contamination.

M. Use standard procedures for containment, cleaning, and decontamination (Environmental Services: II) (293). Category IC (OSHA 29 CFR 1910.1030 § d.4.ii.A)

1. Wear PPE appropriate for a surface decontamination and cleaning task (293).
2. Discard used PPE by using routine disposal procedures or decontaminate reused PPE as appropriate (293,336). Category IC (OSHA 29 CFR 1910.1030 § d.3.v)

Recommendations ---Environmental Sampling

I. General Information

A. Do not conduct random, undirected, microbiologic sampling of air, water, and environmental surfaces in healthcare facilities (270,343). Category IB

B. When indicated, conduct microbiologic sampling as part of an epidemiologic investigation or during assessment of hazardous environmental conditions to detect contamination or verify abatement (270,343). Category IB

C. Limit microbiologic sampling for quality assurance purposes to 1) biologic monitoring of sterilization processes; 2) monthly cultures of water and dialysate in hemodialysis units; and 3) short-term evaluation of the impact of infection control protocols (270,343). Category IB

II. Air, Water, and Environmental Surface Sampling

A. When conducting any form of environmental sampling, identify existing comparative standards and fully document departures from standard methods (343--347). Category II

B. Select a high-volume air sampling device if anticipated levels of microbial airborne contamination are expected to be low (345,346,348,349). Category II

C. Do not use settle plates to quantify the concentration of airborne fungal spores (348). Category II

D. When sampling water, choose growth media and incubation conditions that will facilitate recovery of waterborne organisms (344). Category II

E. When using a sample/rinse method for sampling an environmental surface, develop and document a procedure for manipulating the swab, gauze, or sponge in a reproducible manner so that results are comparable (347). Category II

F. When environmental samples and patient specimens are available for comparison, perform the laboratory analysis on the recovered microorganisms down to the species level at a minimum, and beyond (343). Category II

Recommendations ---Laundry and Bedding

I. Employer Responsibilities

A. Employers must launder workers' personal protective garments or uniforms contaminated with blood or other potentially infectious materials (293). Category IC (OSHA 29 CFR 1910.1030 § d.3.iv)
II. Laundry Facilities and Equipment

A. Maintain the receiving area for contaminated textiles at negative pressure compared with AIA construction standards in effect during the time of facility construction (AIA: 7.23.D4; OSHA: 29 CFR 1910.1030 § d.2.iv).

B. Ensure that laundry areas have handwashing facilities and products and appropriate PPE available for workers (AIA: 7.23.D4; OSHA: 29 CFR 1910.1030 § d.2.iv).

C. Use and maintain laundry equipment according to manufacturers’ instructions (AIA: 7.23.D4; OSHA: 29 CFR 1910.1030 § d.2.iv).

D. Do not leave damp textiles or fabrics in machines overnight (AIA: 7.23.D4; OSHA: 29 CFR 1910.1030 § d.2.iv).

E. Disinfection of washing and drying machines in residential care is not needed as long as gross soil is removed from items before washing and proper washing and drying procedures are used (AIA: 7.23.D4; OSHA: 29 CFR 1910.1030 § d.2.iv).

III. Routine Handling of Contaminated Laundry

A. Handle contaminated textiles and fabrics with minimum agitation to avoid contamination of air, surfaces, and persons (OSHA: 29 CFR 1910.1030 § d.4.iv).

B. Bag or otherwise contain contaminated textiles and fabrics at the point of use (OSHA: 29 CFR 1910.1030 § d.4.iv).

1. Do not sort or prerinse contaminated textiles or fabrics in patient-care areas (OSHA: 29 CFR 1910.1030 § d.4.iv).

2. Use leak-resistant containment for textiles and fabrics contaminated with blood or body substances (OSHA: 29 CFR 1910.1030 § d.4.iv).

3. Identify bags or containers for contaminated textiles with labels, color coding, or other alternative means of communication as appropriate (OSHA: 29 CFR 1910.1030 § d.4.iv).

C. Covers are not needed on contaminated textile hampers (OSHA: 29 CFR 1910.1030 § d.4.iv).

D. If laundry chutes are used, ensure that they are properly designed, maintained, and used in a manner to minimize dispersion of aerosols from contaminated laundry (AAMI: ANSI/AAMI ST65:2000).

1. Ensure that laundry bags are closed before tossing the filled bag into the chute (AAMI: ANSI/AAMI ST65:2000).


E. Establish a facility policy to determine when textiles or fabrics should be sorted (AAMI: ANSI/AAMI ST65:2000).

IV. Laundry Process

A. If hot-water laundry cycles are used, wash with detergent in water >160°F (>71°C) for >25 minutes (AIA: 7.23.D4; OSHA: 29 CFR 1910.1030 § d.2.iv).

B. No recommendation is offered regarding a hot-water temperature setting and cycle duration for items laundered in residential-style health-care facilities. Unresolved issue (AIA: 7.23.D4; OSHA: 29 CFR 1910.1030 § d.2.iv).


D. Choose chemicals suitable for low-temperature washing at proper use concentration if low-temperature (<160°F [<70°C]) laundry cycles are used (AIA: 7.23.D4; OSHA: 29 CFR 1910.1030 § d.2.iv).

E. Package, transport, and store clean textiles and fabrics by methods that will ensure their cleanliness and protect them from dust and soil during interfacility loading, transport, and unloading (AIA: 7.23.D4; OSHA: 29 CFR 1910.1030 § d.2.iv).

V. Microbiologic Sampling of Textiles

A. Do not conduct routine microbiologic sampling of clean textiles.
B. Use microbiologic sampling during outbreak investigations if epidemiologic evidence indicates a role for health-care textiles and clothing in disease transmission (371). Category IV

VI. Special Laundry Situation

A. Use sterilized textiles, surgical drapes, and gowns for situations requiring sterility in patient care (114). Category IB

B. Use hygienically clean textiles (i.e., laundered, but not sterilized) in neonatal intensive care units (292, 372). Category IB

C. Follow manufacturers' recommendations for cleaning fabric products, including those with coated or laminated surfaces. Category II

D. Do not use dry cleaning for routine laundering in health-care facilities (373--375). Category II

E. Use caution when considering use of antimicrobial mattresses, textiles, and clothing as replacements for standard bedding and other fabric items; EPA has not approved public health claims asserting protection against health-care-associated infections for these products (376). Category II

F. No recommendation is offered regarding using disposable fabrics and textiles versus durable goods. Unresolved issue

VII. Mattresses and Pillows

A. Keep mattresses dry; discard them if they remain wet or stained, particularly in burn units (377--382). Category IB

B. Clean and disinfect mattress covers by using EPA-registered disinfectants that are compatible with the materials to prevent the development of tears, cracks, or holes in the covers (377--382). Category IB

C. Maintain the integrity of mattress and pillow covers. Category II

1. Replace mattress and pillow covers if they become torn or otherwise in need of repair. Category II

2. Do not stick needles into a mattress through the cover. Category II

D. Clean and disinfect moisture-resistant mattress covers between patient use by using EPA-registered disinfectants (382). Category IB

E. If using a mattress cover completely made of fabric, change these covers and launder between patient use (377--382). Category IB

F. Launder pillow covers and washable pillows in the hot-water cycle between patients or when they become contaminated with body substances (382). Category IB

VIII. Air-Fluidized Beds

A. Follow manufacturers' instructions for air-fluidized bed maintenance and decontamination. Category II

B. Change the polyester filter sheet at least weekly or as indicated by the manufacturer (383--386). Category II

C. Clean and disinfect the polyester filter sheet thoroughly, especially between patients, using an EPA-registered product (383--386). Category IB

D. Consult the facility engineer to determine the proper placement of air-fluidized beds

Recommendations --- Animals in Health-Care Facilities

I. General Infection-Control Measures for Animal Encounters

A. Minimize contact with animal saliva, dander, urine, and feces (388--390). Category II

B. Practice hand hygiene after any animal contact (146, 270). Category II

1. Wash hands with soap and water, especially if hands are visibly soiled or contaminated with proteinaceous material (146). Category II

2. Use either soap and water or alcohol-based hand rubs when hands are not visibly soiled or contaminated (146). Category II

II. Animal-Assisted Activities and Resident Animal Programs

A. Avoid selection of nonhuman primates and reptiles in animal-assisted activities, animal-assisted therapy, or resident animal programs (391--393). Category II

B. Enroll animals that are fully vaccinated for zoonotic diseases and that are healthy, clean, well-groomed, and negative for enteric parasites or otherwise have completed recent anthelmintic treatment under the regular care of a veterinarian (391, 394). Category II
C. Enroll animals that are trained with the assistance or under the direction of persons who are experienced in this field. (391,394)

D. Ensure that animals are controlled by persons trained in providing activities or behavior traits. (391,394)

E. Take prompt action when an incident of biting or scratching by an animal occurs during an animal-assisted activity or therapy.

1. Remove the animal permanently from these programs. (391)
2. Report the incident promptly to appropriate authorities (e.g., infection control personnel) (391).
3. Promptly clean and treat scratches, bites, or other breaks in the skin. (391)

F. Perform an ICRA and work actively with the animal handler before conducting an animal-assisted activity or therapy to determine whether the session should be held in a public area of the facility or in individual patient rooms. (391,394)

G. Take precautions to mitigate allergic responses to animals.

1. Minimize shedding of animal dander by bathing animals <24 hours before a visit. (391)
2. Groom animals to remove loose hair before a visit, or use a therapy animal cape. (395)

H. Use routine cleaning protocols for housekeeping surfaces.

I. Restrict resident animals, including fish in tanks, from access to patient-care areas, sterile supply areas, sterile and clean supply storage areas, medication preparation areas, operating rooms, isolation areas, and PE areas. (391)

J. Establish a facility policy for regular cleaning of fish tanks, rodent cages, and bird cages, and assign the cleaning task to a nonpatient-care staff member; avoid splashing tank water or contaminating environmental surfaces with animal bedding. (391)

III. Protective Measures for Immunocompromised Patients

A. Advise patients to avoid contact with animal feces, saliva, urine, or solid litter box material. (396)

B. Promptly clean and treat scratches, bites, or other wounds. (396)

C. Advise patients to avoid direct or indirect contact with reptiles. (397)

D. Conduct a case-by-case assessment to determine if animal-assisted activities or animal-assisted therapy programs are appropriate for immunocompromised patients. (394)

E. No recommendation is offered regarding permitting pet visits to terminally ill immunocompromised patients outside their PE units. Unresolved issue.

IV. Service Animals

A. Avoid providing facility access to nonhuman primates and reptiles.

B. Allow service animals access to the facility in accordance with the Americans with Disabilities Act of 1990, unless the presence of the animal creates a direct threat to other persons or a fundamental alteration. (389,398)

C. When a decision must be made regarding a service animal's access to any part of the facility, patient, and health-care situation on a case-by-case basis to determine reasonable modifications in policies and procedures will mitigate this risk. (398, 36.208)
D. If a patient must be separated from his or her service animal while in the health-care facility 1) ascertain from the person what arrangements have been made for supervision or care of the animal during this period of separation; and 2) make appropriate arrangements to address the patient's needs in the absence of the service animal.

V. Animals as Patients in Human Health-Care Facilities

A. Develop health-care facility policies to address the treatment of animals in human health-care facilities.

1. Use the multidisciplinary team approach to policy development, including public media relations efforts to disclose and discuss these activities. Category II

2. Exhaust all veterinary facility, equipment, and instrument options before undertaking the procedure. Category II

3. Ensure that the care of the animal is supervised by a licensed veterinarian. Category II

B. When animals are treated in human health-care facilities, avoid treating animals in operating rooms or other patient care areas where invasive procedures are performed (e.g., cardiac catheterization laboratories or invasive nuclear medicine areas). Category II

C. Schedule the animal procedure for the last procedure of the day in the area, at a time when human patients are not scheduled to be in the vicinity. Category II

D. Adhere strictly to standard precautions. Category II

E. Clean and disinfect environmental surfaces thoroughly by using an EPA-registered product. Category II

F. Allow sufficient ACH to clean the air and help remove airborne dander, microorganisms, and allergens (Table 1). Category II

G. Clean and disinfect using EPA-registered products or sterilize equipment that has been in contact with the animal; or use disposable equipment. Category II

H. If reusable medical or surgical instruments are used in an animal procedure, restrict future use of these instruments to animals only. Category II

VI. Research Animals in Health-Care Facilities

A. Use animals obtained from quality stock, or quarantine incoming animals to detect zoonotic diseases. Category II

B. Treat sick animals or remove them from the facility. Category II

C. Provide prophylactic vaccinations, as available, to animal handlers and contacts at high risk. Category II

D. Ensure proper ventilation through appropriate facility design and location (399). Category IC (USDA: 7 USC 2131)

1. Keep animal rooms at negative pressure relative to corridors (399). Category IC (USDA: 7 USC 2131)

2. Prevent air in animal rooms from recirculating elsewhere in the health-care facility. Category IC (USDA: 7 USC 2131)

E. Keep doors to animal research rooms closed. Category II

F. Restrict access to animal facilities to essential personnel. Category II

G. Establish employee occupational health programs specific to the animal research procedures specific to zoonoses with occupational health clinics in the health-care facility. Health and Human Services [DHHS]: Biosafety in Microbiological and Biomedical Laboratories [BMBL]; OSHA: 29 CFR 1910.1030.132-139

1. Conduct routine employee training on worker safety concerns relevant to the animal facility. Category II
animal handling) (400, 401). Category IC (DHHS: BMBL;
J. Use precautions to prevent development of animal-induced asthma in an
Recommendations --- Regulated Medic
I. Categories of Regulated Medical
A. Designate the following as major categories of medical waste that require special handling and disposal precautions: 1) laboratory wastes [e.g., cultures and stocks of microorganisms]; 2) bulk blood, blood products, blood, and bloody body fluid specimens; and 4) sharps [e.g., needles]
B. Consult federal, state, and local regulations to determine if other waste items
Category IC (States; OSHA: 29 CFR 1910.1030 § g.2.1; Department of Trans
CO23.8)
II. Disposal Plan for Regulated Medical
A. Develop a plan for the collection, handling, predisposal treatment, and terminal disposal (293, 404). Category IC (States; OSHA: 29 CFR 1910.1)
B. Designate a person or persons as responsible for establishing, monitoring,
III. Handling, Transporting, and Storing Regulated Medical Wastes
A. Inform personnel involved in handling and disposal of potentially infective waste are trained in appropriate handling and disposal methods (293). Category IC (OSHA: 29 CFR 1910.1030 § d.2.vii)
B. Manage the handling and disposal of regulated medical wastes generated in isolation areas for the use of regulated medical wastes from other patient-care areas
C. Use proper sharps disposal strategies (293). Category IC (OSHA: 29 CFR 1910.1030 § d.4.iii.A)
1. Use a sharps container capable of maintaining its impermeability after wastefulness is maintained (293). Category IC (OSHA: 29 CFR 1910.1030 § d.4.iii.A)
2. Place disposable syringes with needles, including sterile sharps that are being discarded, into puncture-resistant containers located as close as practical to the point of use (293). Category IC (OSHA: 29 CFR 1910.1030 § d.2 vii)
3. Do not bend, recap, or break used syringe needles before discarding them into a sharps container (36, 293)
D. Store regulated medical wastes awaiting treatment in a properly ventilated area to prevent development of noxious odors. Category IC (OSHA: 29 CFR 1910.1030 § d.2.vii and § d.2)
E. If treatment options are not available at the site where the medical waste is generated, transport regulated medical wastes in closed, impervious containers to the on-site treatment location or to another facility
IV. Treatment and Disposal of Regulated Medical Wastes
A. Treat regulated medical wastes by using a method (e.g., steam sterilization technology) approved by the appropriate authority having jurisdiction (Administration) before disposal in a sanitary landfill
B. Follow precautions for treating microbiologic wastes (e.g., amplified cultures at BMBL)
1. Biosafety level 4 laboratories must inactivate microbiologic wastes in the laboratory by using an approved inactivation method (e.g., autoclaving) before transport to and disposal in a sanitary landfill (400). Category IC.

2. Biosafety level 3 laboratories must inactivate microbiologic wastes in the laboratory by using an approved inactivation method (e.g., autoclaving) or incinerate them at the facility before transport to and disposal in a sanitary landfill (400). Category IC (DHHS: BMBL).

C. Biosafety levels 1 and 2 laboratories should develop strategies to inactivate an approved inactivation method (e.g., autoclaving) instead of packaging and shipping untreated wastes to an offsite facility for treatment and disposal (400,406--408). Category II.

D. Laboratories that isolate select agents from clinical specimens must comply with federal regulations for receipt, transfer, management, and appropriate disposal of these agents (409). Category IC (DHHS: 42 CFR 72 § 72.6.i.1.iii).

E. Sanitary sewers may be used for safe disposal of blood, suctioned fluids, ground tissues, excretions, and secretions, provided that local sewage discharge requirements are met and that the state has declared this to be an acceptable method of disposal (410). Category II.

V. Special Precautions for Wastes Generated During Care of Patients with Rare Diseases

A. When discarding items contaminated with blood and body fluids from VHF patients, contain these regulated medical wastes with minimal agitation during handling (36,109). Category II.

B. Manage properly contained wastes from areas providing care to VHF patients in accordance with recommendations for other isolation areas (Regulated Medical Waste: III B) (36).

C. Decontaminate bulk blood and body fluids from VHF patients by using approved inactivation methods (e.g., autoclaving or chemical treatment) before disposal (36,109). Category IC, II (States).

D. When discarding regulated medical waste generated during the routine (i.e., nonsurgical) care of CJD patients, contain these wastes and decontaminate them by using approved inactivation methods (e.g., autoclaving or incineration) appropriate for the medical waste category (e.g., blood, sharps, or pathological waste) (36,270,273,336). Category IC, II (States).

E. Incinerate medical wastes (e.g., central nervous system tissues or contaminated disposable materials) from brain autopsy or biopsy procedures of diagnosed or suspected CJD patients (340,342). Category IB.

References


7. Beck-Sagué CM, Dooley SW, Hutton MD, et al. Hospital outbreak of multidrug-
transmission to staff and HIV-infected patients.  


22. Jarvis WR. Nosocomial transmission of multidrug-resistant Mycobacterium.  

23. Jarvis WR. Nosocomial transmission of multidrug-resistant Mycobacterium.  


27. CDC. Guidelines for prevention of nosocomial pneumonia.  


34. CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis. MMWR 1994;43(No. RR-13).


37. CDC. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR 2000;49(No. RR-10).


65. Ottney TC. Particle management for HVAC systems. ASHRAE J 1993;35:26--34.


94. Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, Gaztelurrutia L, Navarro JJ. I strain isolated from a patient who underwent heart surgery and two environn


120. Ad Hoc Committee of the Committee on Trauma, Division of Medical Sciences, National Academy of Sciences---National Research Council. Postoperative wound infections: the influence of ultraviolet irradiation of the operating room and of various other factors. Ann Surg 1964;160(suppl):1--192.


125. Taylor GJ, Bannister GC, Leeming JP. Wound disinfection with u...

126. Ayliffe GA. Role of the environment of the operating suite in surgical wounds. Occup Safety and Health Administration. 29 CFR 1910.139. Resp


129. Burroughs HE. Sick building syndrome: fact, fiction, or facility? In: Hi...


205. Breiman RF, Fields BS, Sanden G, Volmer L, Meier A, Spika JS. Association of amoebae. JAMA 1990;263:


209. Schoonmaker D, Heimberger T, Birkhead G. Comparison of ribotypin electrophoresis for distinguishing Legionella pneumophila isolates obtained during the 8th.


211. CDC. Sustained transmission of nosocomial Legionnaires Disease.


CDC. Epidemiologic notes and reports: outbreak of viral gastroenteritis among staff of health care facilities - Pennsylvania and Delaware. MMWR 1987;36:709--11.


Manangan LP, Anderson RL, Arduino MJ, Bond WW. Sanitary care


250. Schmidt OW, Cooney MK, Foy HM. Adeno-associated virus in adenovir

251. McCandlish R, Renfrew M. Immersion in water during labor and l

252. White CG. Chemistry of chlorination [Chapter 4]. In: Handbook of Chlo

253. Muscarella LF. Automatic flexible endoscope reprocessors. G:

254. Muscarella LF. Anticipated reliability of liquid chemical sterilar

255. Muscarella LF. Déjà vu . . . all over again? The importance of instru


256. Gubler JG, Salfinger M, von Graevenitz A. Pseudoepidemic of nontuberc
cleaning machine: report of an outbreak and review of the


258. Muscarella LF. Application of environmental sampling to flexible endosc

dream? J Hosp Infect 1998;3!


264. CDC. Statement from CDC regarding biofilm and dental unit water qua Services, Public Health Service, ( CDC. Recommended infection-control practices for dentists)

265. Office of Safety and Asepsis Procedures Research Foundation. Dental uni Available at http://www.osap.org/issues/pa

266. US Environmental Protection Agency. National Primary Drinking Wa Available at http://www.epa.gov/safey


268. Shearer BG. Biofilm and the dental office

269. Garner JS, Favero MS. CDC guideline for handwashing and hospital

270. US Environmental Protection Agency. Federal Insecticide, Fungicide, and


278. US Food and Drug Administration. Medical devices: adequate directions for use. 21 CFR Part 801.5, 807.87.e.


294. Martin LS, McDougal JS, Loskoski SL. Disinfection and inactivation


301. CDC. Recommendations for prevention of HIV transmission in health care settings. MMWR 1987;36(Suppl No. 2S).


316. Laszlo A. Technical guide: sputum examination for tuberculosis by direct


354. Joint Committee on Healthcare Laundry Guidelines. Guidelines for health Association of America, 1'


356. Association for the Advancement of Medical Instrumentation. Processing 


359. Michaelsen GS. Designing linen chutes to reduce spread of infect.

360. Hoch KW. Laundry chute cleaning recommendation.


363. Walter WG, Schillinger JE. Bacterial survival in laundered linen.

364. Belkin NL. Aseptics and aesthetics of chlorine bleach: can its use in l:

1998;26:149--51.


366. Jaska JM, Fredell DL. Impact of detergent systems on bacterial sur

1980;8:204--9.

367. Battles DR, Vesley D. Wash water temperature and sanitation in the

368. Christian RR, Manchester JT, Mellor MT. Bacteriological quality of fa

369. Smith JA, Neil KR, Davidson CG, Davidson RW. Effect of water tem-

370. Tompkins DS, Johnson P, Fittall BR. Low-temperature washing of patie


372. Meyer CL, Eitzen HE, Schreiner RL, Gfell MA, Moye L, Kleiman MB. St

373. Wagg RE. Disinfection of textiles in laundering and dry clean

with bacteria and viruses. J Hosp Infect 1985;15

1991;337:488.

375. Oehnel E. Drycleaning in the hospital laund

376. US Environmental Protection Agency. Consumer Products Treated wit

http://www.epa.gov/pesticides/f;

377. Fujita K, Lilly HA, Kidson A, Ayliffe GA. Gentamicin-resistant Pseudom


378. Grubb DJ, Watson KC. Pseudomonas septicaemia from pla

379. Sherertz R, Sullivan ML. An outbreak of infections with Acinetobacter i
mattresses. J Infect Dis 1985;15

380. Ndawula EM, Brown L. Mattresses as reservoirs of epidemic methic

381. O'Donoghue MA, Allen KD. Costs of an outbreak of wound infections

382. Weernink A, Severin WP, Tjernberg I, Dijkshoorn L. Pillows, an unexpect

383. Scheidt A, Drusin LM. Bacteriologic contamination in an a

384. Freeman R, Gould FK, Ryan DW, Chamberlain J, Sisson PR. Nosocom


396. CDC. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR 1999;48(No. RR-10).


410. CDC, Office of Biosafety, Hospital Infections Program. Recommendations and Human Services, CDC, 1998.

Table 1